GB2475579A - Dipstick immunoassay with capture zone comprising immobilised hapten - Google Patents
Dipstick immunoassay with capture zone comprising immobilised hapten Download PDFInfo
- Publication number
- GB2475579A GB2475579A GB1010247A GB201010247A GB2475579A GB 2475579 A GB2475579 A GB 2475579A GB 1010247 A GB1010247 A GB 1010247A GB 201010247 A GB201010247 A GB 201010247A GB 2475579 A GB2475579 A GB 2475579A
- Authority
- GB
- United Kingdom
- Prior art keywords
- hapten
- antibody
- zone
- dip stick
- antibody against
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000003018 immunoassay Methods 0.000 title abstract description 3
- 239000000463 material Substances 0.000 claims abstract description 96
- QGLZXHRNAYXIBU-WEVVVXLNSA-N aldicarb Chemical compound CNC(=O)O\N=C\C(C)(C)SC QGLZXHRNAYXIBU-WEVVVXLNSA-N 0.000 claims abstract description 15
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims abstract description 12
- 239000012466 permeate Substances 0.000 claims abstract description 12
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 claims abstract description 11
- 229940025084 amphetamine Drugs 0.000 claims abstract description 11
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 claims abstract description 10
- 229960001252 methamphetamine Drugs 0.000 claims abstract description 10
- FIKAKWIAUPDISJ-UHFFFAOYSA-L paraquat dichloride Chemical compound [Cl-].[Cl-].C1=C[N+](C)=CC=C1C1=CC=[N+](C)C=C1 FIKAKWIAUPDISJ-UHFFFAOYSA-L 0.000 claims abstract description 9
- 229960003920 cocaine Drugs 0.000 claims abstract description 5
- 231100000678 Mycotoxin Toxicity 0.000 claims abstract 2
- 239000002636 mycotoxin Substances 0.000 claims abstract 2
- 238000003556 assay Methods 0.000 claims description 41
- 229920001223 polyethylene glycol Polymers 0.000 claims description 31
- 239000007788 liquid Substances 0.000 claims description 17
- 239000002202 Polyethylene glycol Substances 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 8
- 239000003344 environmental pollutant Substances 0.000 claims description 5
- 239000011859 microparticle Substances 0.000 claims description 5
- 229920000642 polymer Polymers 0.000 claims description 5
- 150000002433 hydrophilic molecules Chemical class 0.000 claims description 4
- 229910000960 colored gold Inorganic materials 0.000 claims description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 abstract description 44
- 239000010931 gold Substances 0.000 abstract description 40
- 229910052737 gold Inorganic materials 0.000 abstract description 40
- 239000012491 analyte Substances 0.000 abstract description 9
- 238000001514 detection method Methods 0.000 abstract description 4
- 239000000872 buffer Substances 0.000 description 29
- 239000012528 membrane Substances 0.000 description 27
- 239000000203 mixture Substances 0.000 description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 24
- 238000000034 method Methods 0.000 description 23
- 239000000243 solution Substances 0.000 description 22
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 21
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 20
- 229920001220 nitrocellulos Polymers 0.000 description 20
- 239000000020 Nitrocellulose Substances 0.000 description 19
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 18
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 18
- 229940079938 nitrocellulose Drugs 0.000 description 18
- 238000012360 testing method Methods 0.000 description 14
- 239000011230 binding agent Substances 0.000 description 13
- 238000000502 dialysis Methods 0.000 description 13
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 12
- 150000002605 large molecules Chemical class 0.000 description 11
- 229920002521 macromolecule Polymers 0.000 description 11
- 239000007983 Tris buffer Substances 0.000 description 10
- 150000002148 esters Chemical class 0.000 description 9
- -1 ethylidineestradiol Chemical compound 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 9
- 235000017557 sodium bicarbonate Nutrition 0.000 description 9
- 229960002685 biotin Drugs 0.000 description 8
- 239000011616 biotin Substances 0.000 description 8
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 239000002250 absorbent Substances 0.000 description 7
- 230000002745 absorbent Effects 0.000 description 7
- 230000008021 deposition Effects 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 7
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 6
- 125000003277 amino group Chemical group 0.000 description 6
- 235000020958 biotin Nutrition 0.000 description 6
- 210000002700 urine Anatomy 0.000 description 6
- HGUFODBRKLSHSI-UHFFFAOYSA-N 2,3,7,8-tetrachloro-dibenzo-p-dioxin Chemical compound O1C2=CC(Cl)=C(Cl)C=C2OC2=C1C=C(Cl)C(Cl)=C2 HGUFODBRKLSHSI-UHFFFAOYSA-N 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 239000003365 glass fiber Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 241000283707 Capra Species 0.000 description 4
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000001745 anti-biotin effect Effects 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 238000005507 spraying Methods 0.000 description 4
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 3
- KZFBHCCLJSAHBQ-UHFFFAOYSA-N Benzoylecgonine Natural products CN1C2CCC1C(C(C2)OC(=C)c3ccccc3)C(=O)O KZFBHCCLJSAHBQ-UHFFFAOYSA-N 0.000 description 3
- 239000005944 Chlorpyrifos Substances 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- SBPBAQFWLVIOKP-UHFFFAOYSA-N chlorpyrifos Chemical compound CCOP(=S)(OCC)OC1=NC(Cl)=C(Cl)C=C1Cl SBPBAQFWLVIOKP-UHFFFAOYSA-N 0.000 description 3
- GVGYEFKIHJTNQZ-RFQIPJPRSA-N ecgonine benzoate Chemical compound O([C@@H]1[C@@H]([C@H]2CC[C@@H](C1)N2C)C(O)=O)C(=O)C1=CC=CC=C1 GVGYEFKIHJTNQZ-RFQIPJPRSA-N 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- 210000003296 saliva Anatomy 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- PVVTWNMXEHROIA-UHFFFAOYSA-N 2-(3-hydroxypropyl)-1h-quinazolin-4-one Chemical group C1=CC=C2NC(CCCO)=NC(=O)C2=C1 PVVTWNMXEHROIA-UHFFFAOYSA-N 0.000 description 2
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 2
- NGBBVGZWCFBOGO-UHFFFAOYSA-N 3,4-Methylenedioxyamphetamine Chemical compound CC(N)CC1=CC=C2OCOC2=C1 NGBBVGZWCFBOGO-UHFFFAOYSA-N 0.000 description 2
- SHXWCVYOXRDMCX-UHFFFAOYSA-N 3,4-methylenedioxymethamphetamine Chemical compound CNC(C)CC1=CC=C2OCOC2=C1 SHXWCVYOXRDMCX-UHFFFAOYSA-N 0.000 description 2
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 238000000035 BCA protein assay Methods 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- 229920002799 BoPET Polymers 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- VAYOSLLFUXYJDT-RDTXWAMCSA-N Lysergic acid diethylamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N(CC)CC)C2)=C3C2=CNC3=C1 VAYOSLLFUXYJDT-RDTXWAMCSA-N 0.000 description 2
- 239000005041 Mylar™ Substances 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 239000003905 agrochemical Substances 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000012888 bovine serum Substances 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000007975 buffered saline Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 229950002454 lysergide Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 229960001797 methadone Drugs 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 229940068917 polyethylene glycols Drugs 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 229910021642 ultra pure water Inorganic materials 0.000 description 2
- 239000012498 ultrapure water Substances 0.000 description 2
- LFRHMTZYADABJZ-UHFFFAOYSA-N 1-(1,3-benzodioxol-5-yl)butan-2-amine;hydron;chloride Chemical compound Cl.CCC(N)CC1=CC=C2OCOC2=C1 LFRHMTZYADABJZ-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- GXVUZYLYWKWJIM-UHFFFAOYSA-N 2-(2-aminoethoxy)ethanamine Chemical compound NCCOCCN GXVUZYLYWKWJIM-UHFFFAOYSA-N 0.000 description 1
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
- GYNXTHOOAGYMOK-UHFFFAOYSA-N 2-hydroxybutanediamide Chemical compound NC(=O)CC(O)C(N)=O GYNXTHOOAGYMOK-UHFFFAOYSA-N 0.000 description 1
- WFBQHUSQUWCBIW-UHFFFAOYSA-N 3-(4-bromobutyl)benzene-1,2-dicarboxamide Chemical compound NC(=O)C1=CC=CC(CCCCBr)=C1C(N)=O WFBQHUSQUWCBIW-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- NQRNDAQIBKFAAK-UFLZEWODSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoic acid;gold Chemical compound [Au].N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 NQRNDAQIBKFAAK-UFLZEWODSA-N 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- WDJUZGPOPHTGOT-OAXVISGBSA-N Digitoxin Natural products O([C@H]1[C@@H](C)O[C@@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@@](C)([C@H](C6=CC(=O)OC6)CC5)CC4)CC3)CC2)C[C@H]1O)[C@H]1O[C@@H](C)[C@H](O[C@H]2O[C@@H](C)[C@@H](O)[C@@H](O)C2)[C@@H](O)C1 WDJUZGPOPHTGOT-OAXVISGBSA-N 0.000 description 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000575946 Ione Species 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- LTXREWYXXSTFRX-QGZVFWFLSA-N Linagliptin Chemical compound N=1C=2N(C)C(=O)N(CC=3N=C4C=CC=CC4=C(C)N=3)C(=O)C=2N(CC#CC)C=1N1CCC[C@@H](N)C1 LTXREWYXXSTFRX-QGZVFWFLSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 241000237988 Patellidae Species 0.000 description 1
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920000297 Rayon Polymers 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012412 chemical coupling Methods 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- XLMALTXPSGQGBX-GCJKJVERSA-N dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 description 1
- 229960004193 dextropropoxyphene Drugs 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- WDJUZGPOPHTGOT-XUDUSOBPSA-N digitoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)CC5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O WDJUZGPOPHTGOT-XUDUSOBPSA-N 0.000 description 1
- 229960000648 digitoxin Drugs 0.000 description 1
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
- 229960005156 digoxin Drugs 0.000 description 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 description 1
- 229960001348 estriol Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- DCPMPXBYPZGNDC-UHFFFAOYSA-N hydron;methanediimine;chloride Chemical compound Cl.N=C=N DCPMPXBYPZGNDC-UHFFFAOYSA-N 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 240000004308 marijuana Species 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- VATIIUARCMKQBJ-ZDUSSCGKSA-N n'-methyl-n'-[(2s)-1-phenylpropan-2-yl]butane-1,4-diamine Chemical compound NCCCCN(C)[C@@H](C)CC1=CC=CC=C1 VATIIUARCMKQBJ-ZDUSSCGKSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
- 229950010883 phencyclidine Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000002964 rayon Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000010865 sewage Substances 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 229940014800 succinic anhydride Drugs 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000003656 tris buffered saline Substances 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
- G01N33/54386—Analytical elements
- G01N33/54387—Immunochromatographic test strips
- G01N33/54388—Immunochromatographic test strips based on lateral flow
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
- G01N33/54386—Analytical elements
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/946—CNS-stimulants, e.g. cocaine, amphetamines
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2430/00—Assays, e.g. immunoassays or enzyme assays, involving synthetic organic compounds as analytes
- G01N2430/10—Insecticides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2430/00—Assays, e.g. immunoassays or enzyme assays, involving synthetic organic compounds as analytes
- G01N2430/20—Herbicides, e.g. DDT
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Peptides Or Proteins (AREA)
Abstract
An immunoassay for a hapten analyte comprises permeable materials 1, 2 having i) a first zone 3 comprising a region of labelled (e.g. gold) antibody 5 specific for the hapten and a region of binding material 6 comprising hapten immobilised by a synthetic hydrophilic material (e.g. PEG) having a molecular mass of over 2000 and ii) a second zone 4 comprising a locating means (e.g. a secondary antibody) having affinity only for the labelled antibody-hapten conjugate. In use a sample comprising aqueous hapten contacts the permeable material at 7 and permeates through the first zone 3 wherein the labelled antibody 5 binds hapten before any unbound labelled antibody is bound by immobilised hapten 6 such that only labelled antibody bound to hapten analyte is permeated to the second zone 4 for detection. Preferably the hapten analyte is cocaine, amphetamine, methamphetamine, aldicarb, paraquat, chlorpyraphos or mycotoxin.
Description
Assay devices arid methods and components for use therein.
Field of the tnventkn.
The present invention relates to assay devices, to methods of assaying haptens and to components useful in such devices and methods. More specifically this invention relates to assay devices using permeable materials, optionally in the form of dick sticks, to methods of use of such devices in the qualitative or quantatative determination of baptens and to chemical entities useful in such devices and methods.
Background to the invention.
A common problem encountered in the assay of baptens is that standard competitive assays produce a signal in inverse proportion to the amount of hapten in the sample suspected of containing the hapten. Thus for when testing a sample that is free of analyte a strong signal is produces whereas when testing a sample containing a äigniticant quantity of the bapten a weak signal is produced. This can lead to difficulty in using such a test in field conditions (for example in the outdoors) and even under laboratory conditions. Also such tests needlo contain a control line that can take a prolonged time to develop so that the result of the assay can be confirmed. A solution to this problem was first suggested in US Patent No. 5,641,690 where it was proposed to employ an additional antibody in the system so that a positive read out could be obtained (that is ont where the grated amount of hapten in the..
sample the greater the signal produced).
The system described in US Patent No. 5,641,690 potentially offered a major improvement but unfortunately has not been commercialised. This has been due in part to considerabló difficulties resulting from the need to prepare a specific antibody
I
against the primary antibody in the. system for each analyt envisaged. Also the backgrounds generally encountered with the embodiments of US Patent No. 5,641,690 have tended to have rendered the results.less than desirable in commercial use.
Furthermore no working examples of lateral flow assays (such as dip sticks) have ever been shown to work employing the system of US Patent No. 5,641690.
Methods which result in an assay which result in the measuring of the number of binding sites not occupied byanalyte are described in W095104231 and W092f 19973.
There is therefore a continuing need to provide an assay for a hapten.in which the signal increases as the concentration of the hapten in the sample being tested increases especially one which can be produced withOut needed to produce a news specific antibody for each analyte as part of the signal generating system and preferably which can be fonnatted as a lateral flow ass such as a dip stick. Such an assay has now been found as have devices for performing the assay and components to use in the assay.
Brief description of the invention.
The present invention provides an assay device which comprises a permeable material such that when as aqueous liquid is contacted with a first part of the permeable material it permeates toa second part of the permeable material, said permeable material having a first zone and a second zOne disposed so that when the aqueoUs liquid is contacted with the first part of the permeable material it passes first through the first zone and then into the second zone as it permeates to the second part of the permeable material; said first zone containing a signal generating means labelled with an antibody against a hapten; said first zone also coôtaining a binding material for said antibody against the hapten; said second ione contains a locating means for said antibody against the hapen such that it binds to the antibody present on the signal generating means labelled with an antibody which has bound hapten but does not bind to antibody present on the signal generating means which has bound the binding material for said antibody against the hapten; the signal generating means being such that a signal is generated on binding to said locating means; wherein: (a) the locating means is not a specific binder for the antibody against the hapten and/or (b) the locating means is an antibody against the Fc region of the antibody against the hapten and/or (c) the binding material for the antibody against the hapten is free of hapten and/or hapten analogue and br (d) the binding material is hapten or close structural analogue covalently bound to a synthetic hydrophilic molecule of molecular weight grater than 2000 and/or (e) the binding material has two hapteri or close structural analogues.
Such devices may be used to determine whether a bapten is present in a sample suspected of containing it and may also be adapted to provide a qualitative measurement of the amount of hapten present.
The assay device is preferably in the form of a dip stick, for example in which the first zone is located towards one end of the dip stick and the second zone is located towards the other end of the dip stick.
The permeable material may be any material that allows the permeation of an aqueous liquid,'for example water, urine, saiiva, blood or plasma. Such materials cam be visibly fibrous, for example such as filter papers, or can be visibly non fibrous, for example cellulose membranes. Permeable membranes for use in assay devices are well known to the skilled worker.
The signal generating means may be any that is visualised on concentration. Apt signal generating means include miàroparticles, for example of polymer or of metal. A preferred signal generating means are coloured latex and gold microparticles of which gold is presently most preferred. The use of gold sols in assay devices such as lateral flcw devices are well known to the skilled worker.
The antibody against the hapten may be attached to the signal generating means in any suitable manner,. for example as well understood by the skilled worker for attaching antibodies to gold microparticles.
*The antibody against the hapten may be a monoclonal or polyclonal antibody. Surprisingly it has been found that polyclonal antibodies are particularly effective in the devices of this invention which, owing to theft ready availability, provides an additional advantage to the invention.
The locating means is preferably not a specific antibody against the antibody against the hapten as this offers a greatly simplified method of putting the invention into operation. The locating means is favourably an antibody against the Fc region of the antibody against the hapten. Preferably the locating means is an anti IgCi antibody. This may be a monoclonal or polyclonal antibody but it is particularly preferred that it is a polyconal antibody.
The binding material against the antibody against the hapten is any which can cOmpete with the hapten for the antibody against the hapten. Generally it is the hapten or a close structural analogue of the hapten covalenfly bound to a molecule that prevents the binding material binding to the locating means when the binding material is bound to the antibody against the hapten. Aptly the molecule to which the hapten or close structural analogue is covalently bound is a large molecule, for example has a molecular weight of 5000daltons or more. Suitable large molecules include peptides, especially proteins, carbohydrates, and synthetic molecules, for example polymers. Favourably the large molecule is hydrophilic, for example polyethylene glycol or modified polyethylene glycol having terminal amino groups. Preferably the binding moans will have been rendered free of hapten or hapten analogue by exhaustive dialysis. Most aptly the binding means has two or more, preferably two, hapten or close structural analogues therein.
The locating means is favourably not an antibody specific to the antibody against the hapten. The locating means is aptly a non-specific antibody, especially against the Fc region of the antibody against the hapten. Preferably the locating means is an anti lgG antibody. Although the locating means may be monoclonal it is preferably polyclonaL The permeable material may be any that permits the movement of the signal. generating means to which hapten or binder is bound through the material to the second zone, Such materials include papers such as filter paper and cellulose membranes, particularly nitrocellulose membranes. Often the device may be comprised of two or more permeable materials. Thus for example a paper may be joined to a cellulose membrane. In such an arrangement the first zone may be on the pape! and the second zone may be on a nitrocel lulose membrane.
In use the assay device is employed by applying an aqueous sample suspected of containing the hapten to a part of the permeable material so that the aqueous liquid permeates first through the first zone and then into the second zone. A detectable signal is produced if the sample contains hapten but not if the, sample does not contain hapten. The intensity of the signal increases with the concentration of the hapten in the sample.
The assay device may be in any suitable geometrical format but.
that of a dip stick is preferred, that is a device that is longer than it is wide If desired the device may be adapted to detect bapten from surfaces, for example from skin. Suitable methods of achieving this are described in the general and patent literature, for example US Patent No 6,514,773 may be consulted for suitable methods.
Description of the drawings.
Figi shows an assay device of the invention in the form of a dip stick. The dip sick has a permeable layer if nitrocellulose (1) and a permeable layer of paper (2). On the paper. layer is a first zone (3) and on the nitrocellulose layer is a second zone (4). The first zone contains a line (5) impregnated with gold labelled with an antibody against the hapten to be analysed, and a line (6).impregnated with binder for the antibody. The second zone (3) contains a non specific antibody against the antibody against the hapten to be analysed. The non-specific antibody will not bind to the antibody against the bapten if it has bound binder. The first zone is placed so as to allow sufficient area for addition of sample in a portion (7) downstream of the first zone. The sample addition portion (7) is impregnated with buffer.
Fig 2 shows an alternative assay device of the invention in which films (8, 9am! 10) of paper (8), nitrocellulose (9) and again glass fiber (10) are employed. The paper film (8) contains the first zone (11) which is comprised of a line (12) impregnated with gold labelled with the antibody against thô bapten and binder (13). The line (12) also contains gold labelled with biotin. The middle film (9) contains the second zone (14) which contains a line (15) of non-specific binder against the antibody labelled on the gold and a line (16) containing an antibody to biotin The films (8, 9 and 10) are mounted on a Mylar backing (16).
Detailed descijption of the invention.
The present invention provides an assay device which comprises a permeable material such that when as aqueous liquid is contacted with a first part of the permeable material it permeates to a second part of the permeable material, said permeable material having a first zone and a second zone disposed so that when the aqueous liquid is contacted with the first part of the permeable material it passes first through the first zone and then into the second zOne as it permeates to the second part of the permeable material; said first zone containing a Signal generating means labelled with an antibody against a hapten said first zone also containing a binding material for said antibody against the hapten; said second zone contains a locating means for said antibody against the hapen such that it binds to the antibody present on the signal generating means labelled with an antibody which has bound hapten but does not bind to antibody present on the signal generating means which has bound the binding material for said antibody against the hapten; the signal generating means being: such that a signal is generated on binding to said locating means; wherein: (a) the locating means is not a specific binder for the antibody against the hapten and/or (b) the locating means is an antibody against the Fc region of the antibody against the hapten and/or (c) the binding material for the antibody against the bapten is free of hapten and/or hapten analogue and for (d) the binding material is hapten or close structural analogue covalently bound to a synthetic bydrophilic molecule of molecular weight grater than 2000 and/or (e) the binding material has two hapten or close structural analogues.
In a presently preferred form the device is one wherein the locating means is a non-specific antibody.
(1)The device.
The device may be in any format that permits lateral flow between the area to which the sample is introduced, the first zone and the second zone. A preferred form of the device will be a "dip stick".
The skilled worker will be aware of many forms of dip stick described in the patent and general literature and many that have been commercialized, at least on a small scale. Such known formats may be employed in this invention since the surprising featurós of this invention relate to the reagents that are added to the dip stick rather than the physical construction of dip sticks themselves (however as will be seen below some particularly preferred forms of the dip stick are independently inventive).
A favoured form of the dip stick will be an elongate strip that is longer than it is wide. Such a dipstick will normally be rectangular.
The length of the dipstick will generally be from 15mm to 100mm, for example at least 18,20, 25, 30, 40, 50, 60,70, 80 or 90mm and less than 70,60, 50, 45,40,35,30,25,20mm. Suitable widths for the dip stick will be from 10 to 50mm (although on some occasions wider dipsticks can be used) for exampleabout 12, 13, 15, 17,20, 22,25,30,35,40 or 45mm. An apt width is 25mm owing to availability from manufactures in reel form. Generally the operative area of the dipstick (the area in use rather than additional area not needed for operation but present for reasons of aesthetics or convenience) will be from about 5 times longer than wide to 20 times longer than wide, for example 6, 7, 8, 9, 10, 12, 15, 17, 18 or 19 times.
Dipsticks for use with highly mobile aqueous liquids suck as water or urine will tend to be shorter than dipsticks for use with more viscous liquids such as saliva or urine. However it is possible to design a dipstick that can be used with both.
The permeable material may be any that permits the reagents to pass from the first zone to the second zone. The skilled worker will be aware of a number of such materials that allow the passage of liquid by capillarity. Many such materials are cellulosic in nature, for example filter paper, cellulose and nitrocellulosç membranes.
Other suitable materials include polyester, glass fibre, rayon nylon, polydivinylfluoride and the like. A particularly apt material is nitrocellulose. Nitrocellulose films of thickness typically used in the manufacture of dipsticks are apt for use in this invention.
A current choice of nitrocellulose membrane is UniSart CN 140 supplied by Sartorius and equivalent materials from other suppliers. Whatman Immunopore may be considered for use. The CM stands for cellulose nitrate and the 140 relates to the average wicking rate for deionised water up a 5 cm length of material.
Faster and slower wicking materials are available for different forms of the assay device. In the devices of the invention different wicking rates affect assay reaction times. Wicking rates will change depending on the nature of the sample type, for example water and urine may employ relatively faster wicking rates and serum and saliva may employ relatively slower wicking rates; The skilled worker will be aware that standard commercially available materials may be used for such aqueous liquids but that intermediate wicking rates are often suitable for all aqueous samples suspected of containing hapten.
Often more than one type of membrane is used in the device. Aptly two different membrane materials are used, for example glass fibre and nitrocellulose,. In such fonns the glass fibre is used in the downstream portion,. for example in the part where the first zone. is located, and the nitrocellulose membrane is used further upstream, for example beyond the first zone and may include the second zone.
The device may also contain a sample collection portion, for example, a projecting highly porous and absorbent section that serves to collect sample to be tested. Such sample collecting means may project from the end on the device downstream of the first zone.
The device may also contain an absorbent material, for example a pad of absorbent material, beyond the second zone to encourage of flow, for example until all the assay sample has been taken up. If the device comprises two layers, then the absorbent material, aptly contacts the layer but has minimal contact with the layer. The absorbent pad is aptly of cellulosic material, for example a porous paper pad.
Also forming part of this invention is a permeable $rip having a zone containing a non specific antibody against an antibody to a hapten for use in the preparation of a device for analysis the hapten. Such a strip may be used in the manufacture of many devices against different haptens by combining with a strip containing a signal generating means labelled with an antibody against the hapten and a binder therefore as described herein.
(2)Signal generating means.
The device may.employ any signal generating means that produces a signal when it becomes immobilized in the second zone by the locating means. The skilled worker will be familiar with many such signal generating means. It is possible to employ means that are readable by machine or by eye.
Although any signal generating means useable in lateral flow devises may be employed it is preferred to use one that allows for direct visual detection by eye. Particulate materials such as microparticles of metals such as gold and latexes are well known to the skilled worker and may be used in the devices of this invention. The general and patent literature contains numerous examples of such materials, for example see EP-14 16275.
The antibody against the hapten can be attached to such particles in standard manner, for example using the methods described in commercial kits sold for this purpose.
(3) The hapten.
The device of this invention may be adapted to be used in the assay of a very wide range of haptens. A hapten is a molecule which is too small to itself give rise to an immune response. For the * purposes of this document a hapten may be considered to be a molecule of molecular weight less than 900daltons and greater than 90 Daltons. Aptly the happen has a molecular weight of 100 to 700 Daltons, for example 120 to 400 Daltons, such as about 150, 180, 250 or 300daltons. Such molecules will normally contain carbon, hydrogen and optionally oxygen and/or nitrogen and sometimes other elements such as sulphur and/or phosphorus.
Suitably the hapten may be medicament, hormone, metabolite (for example of a drug of abuse or medicament), toxin, pollutant, substances found in food and drink, substances found in water courses and sewage, substances used for source and product identification or a drug of abuse or other any such hapten that is chosen to be assayed.
Suitable drugs of abuse to be assayed include amphetamine, methamphetamine, 4-methylenedioxyamphetamine (MDA), 3,4- dirnethylenedioxymethamphetamine (MDMA, ecstasy). 3,4-methylenedioxyethylamphetamine, tetradydrocanabiniol (THC, cannabis), cocaine, lysergic acid diethylamide (LSD), ketamine, opiodes such as morphine, methadone, Metabolites which occur after ingestion of such drugs are also suitable haptens, for example benzoylecgogonine (BE) which is a metabolite of cocaine.
A particularly suitable hapten is benzoylecoconine as its presence in a sample derived from a person enables the identification of cocaine use by that person.
Examples of haptens also include phencyclidine, acetaminophen, barbiturates, benzodiazepines, methadone, propoxyphene, tricyclic ántidepressants, digoxin, digitoxin, agrochemicals such as those in Agrochemical Desk Reference?' ED. J.H. Montgomery, CRC Press LLC 1997, vitamins, natural toxins such as micromycins and mycotocins, hormones such as estradiol, estratriol, ethylidineestradiol, testosterone and the like.
(4) Antibody against hapten.
The antibody against the hapten may be a polyclonal or monoclonal antibody. Many antibodies are commercially available and it is one of the great advantages of this invention that many commercial antibodies may be employed rather than having to raise a new antibody for each happen to be employed. However thee will be some baptens for which no commercial antibody is available. In such a case the antibody may be produced by the conventional methods known to the skilled worker. The antibody may be the whole antibody or a fragment thereof as long as the locating means is selected to recognise that fragment. Preferably * however the antibody is the whole antibody including the Fc portion as the locating means preferably binds nonspecifically to *the Fe region of the antibody. The antibody may be of any class and may be obtained from commercial sources or made by the skilled worker using standard methods.
The antibody will be sufficiently specific so that it will not also pick up other haptens that that may occur in a sample in an unwanted manner leading to Ihlse positives. This is wólI understood to the skilled worker as use of specific antibodies is the basis of standard commercial assay systems. The antibody may be selected to be specific epitope found in the test hapten alone or in several closely related haptens that may be tested for, forexample as in the case of various amphetamine derivates that may be wished to be identified as a class rather than by individual member.
(5) The locating means.
The locating means is preferably not a specific antibody against the antibody against the hapten as this offers a greatly simplified method of putting the invention into operation. The locating means is favourably an antibody against the Fcregion of the antibody against the haptón. Alternatively the locating means can be an antibody against the other regions of antibody against the hapten such as the Fab or Fv regions.
The locating means may be a monoclonal or polyclonal antibody but it is particularly preferred that it is a polyclonal antibody.
Preferably the locating means is an anti IgO antibody. Also 1gM, IgA, IgE and sub-classes are also envisaged for use. Sinng]e chain Fv agents from, for example, cainelids and isolated antibody heavy chain are also envisaged for use. The antibodies may be natural of recombinant antibodies.
Non antibody locating means envisaged for use in the invention include molecular imprints (mops), aptamers and substances which non-specifically bind antibody such as protein A and protein G and the like.
The use of a non specific antibody results in considerable benefits in that the difficult to prepare selective antibodies referred to in the prior can be avoided. This benefit is particularly useful when a series of assay devise against different haptens are being produced.
The benefit is similarly particularly useful when as assay devise is constructed for use against two or more types type of hapten since a single locating means can be employed.
(5).The binder.
The binding material against the antibody against the hapten is any which can compete with the hapten for the antibody against the hapten. Generally it is the hapten or a close structural analogue of the hapten covalently bound to a molecule that prevents the binding material binding to the locating means when the material is bound to the antibody against the hapten.
The close structural analogue will be a molecule that retains the same binding sites as the hapten so that it binds to the antibody against the hapten.
Aptly the molecule to which the hapten or close structural analogue is covalently bound is a large molecule, for example has a molecular weight of 5,000 daltons or more. Suitable large molecules include peptides, especially proteins, carbohydrates, and synthetic molecules, for example polymers. Favourably the large molecule is hydrophilic, for example polyethylene glycol or modified polyethylene glycol having tenninal amino groups.
Protein molecules that are used in conventional immunoassays to link to hapten or hapten analogues may also be employed, for example keyhole limpet heamocyanin, bovine serum albumen and like proteins. Such proteins can have molecular weights of, for example, 20,000 daltons to 2,000,000 daltons.
Apt blockers include polyethylene glycols of molecular weight 2,000 daltons or more, for example 5,000 daltons or more, 10,000 daltons or more, 15,000 daltons or more, 20,000 daltons or more but generally of molecular weight 60,000 daltons or less, for example 40000daltOns or less, aptly 30,000daltons or less.
So far identified particularly suitable polyethyleneglycols for use are of molecular weight 20,000 daltons. Suitable commercial source of such a material include Sigma.
For ease in the covalent binding of the hapten or close structural analogue polyethyleglycols (or other synthetic polymer) is modified to have terminal amino groups.
Hapten or hapten analogue may be covalently linked to the large molecule by standard methods of chemical coupling known to the skilled chemist. Typically methods of forming ester, ami4e, ether or like links can be employed. A method that is presently favoured comprises adding a readily displaceable group to the hapten or hapten analogue, for example a readily displaceable ester groUp. A presently favoured method is to couple a hydrolysuccinamide group to a carboxylic acid group, for example with a coupling agent such as a carbodilmide such as dicyclohexylcarbodiimide or 1 -ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC). Such reactions can sometimes be carried out in media containing water but it can be useful to employ a dry solvent such as dioxan or dimethylformainide. The active intennediated can then be reacted with the large molecule, for example with an amino or hydroxyl group in such a large molecule. This stage can often be carried out in a solvent such as water, for example in the presence of a buffer or base such as sodium bicarbonate.
Preferably the binding means will have been rendered free of hapten or hapten analogue by exhaustive dialysis. It has been found that a conventional level of dialysis, .for example for.24 hours employing common commercial dialyse membrane, leads to assays with a high background that reduces the usefulness, Method successfully employed for rendering the binder free of hapten include dialysis using standard commercial dialysis membrane for ten days or more, for example 20 or 30 days. An alternative and convenient method is to employ spin methods.
Most aptly the binding means has two or more, preferably two, hapten or close structural analogues therein. In experiments carried out to date it appears that the divalent blocker produces better results than the monovalent blockers.
Binders can be checked against the antibody on the gold by binding assays known to the skilled worker or by emplying in a dip stick with all other components present o check for effectiveness of the assay.
The binding means will move through the dip stick as the aqueous sample permeates through the nitrocellulose or other membrane material. Since it does not bind to the locating means the binder does not have to be fixed to an area of the lateral flow devise and this appears to enhance the effectiveness of the device allowing for a signal line of considerable intensity. This in turn enables the detection of lower concentrations of hapten that is normally the case in dip sticks, for example allowing the assay to be read by eye even in difflcult lighting.conditions, for example under some street lights.
(6). Control Signal and Quantification.
The device may also be provided with a control means that can serve as confirmation of effective working and for which can be used to help provide and estimate of measurement of the amount of hapten in the sample.
Asa check to make sure that the aqueous liquid is permeating the device and that signal generating means is travelling to the second zone, a second signal generating means and a means for locating it and thereby producing a signal may be employed. The second signal generating means may be labelled with a member of a binding pair and the other member of the binding pair placed in the device on the other side of the second zone from the first zone.
The signal generating means need not be the same as the first signal generating means but it is convenient that it is. Thus for example is the signal generating means labelled with an antibody against the hapten is gold particles then the second signal generating means is also conveniently gold particles. Such particles may be essentially identical to those of the first signal generating means or they may be somewhat different.
The binding pair may be any suitable pair such as a ligand and receptor, fir example where the one is an antibody and the other a substance to which the antibody binds. However, in is preferred at present to employ biotin and a binding partner therefore such as avadin or and anti-biotin antibody as the members of the pair. It has been found that biotin conjugated to a protein such as bovine serum albumin can be coated on to gold particles and the coated particles applied to the first zone. A line of anti-biotin antibody may be provided beyond the second zone. When in use, the aqueous liquid permeated beyond the second zone and reaches the line of anti-biotin antibody, gold particles labelled with biotin become located and produce a visible signal. This confirms that the device is allowing gold to permeate past the second zone.
Comparison as standard control line to sample line can be used to estimate the concentration of happen in the sample..
(7) Assay method.
In use the assay may be used in a manner known to the skilled worker. Thus for example a sample suspected of containing the hapten can be introduced tothe bottom of the dip stick. . This can be in conventional liquid such as saliva or urine or can be produced by wiping an absorbent material across a surface, for example skin, and then transferred to the device in known manner.
Examples
Example 1.
Benzoylecgonine Polyoxyethylene Blocker.
Benzoylecgonine (BE) (4mg) was dissolved in dry dioxin (SOOul) abd N-bydroxysuccinamide (NHS) (4mg) added. I -EthyI-343-dimethylaminopropul)carbodiimide hydrochloride (8mg) was suspended/dissolved in dioxan (Imi) and immediately added to the mixture. The mixture was shaken at ambient temperature for 2 hours (to form BE-succinantide). To this was added diamino terminated polyethyleneglycol (mol. wt. 20,000) dissolved in I ml of 0. lM sodium bicarbonate solution. The solution was left overnight (about l6hrs) and was then diluted with tris/triton buffer.
The above blocker was dialysed with 5 changes at 4 degrees C. It was then spun in a 10,000 mol. wt. cut-off spin column. The dialysis buffer was 50mM TRIS buffer (Sigma Cat no. T1503) pH 7.4 pIus 0.O0Triton X 110 (Sigma cat. No. T9284. The method was as follows.
1) The diRE-PEG sample was placed ha 10,000 mol. wt. cut off dialysis cassette (Pierce Slide-a-lyser Cat. no. 66830. 2) The dialysis cassette was placed in 51 of dialysis buffer. 3) The buffer was changed at 4hrs. 4)The buffer was changed at 8 tin and lest overnight. 5) Next morning the buffer was changed and left overnight. 6) Step 5 was repeated twice more. Then, 6)1 5m1 * aliquots of the blocker are placed inVivaspin l5R 10,000 mol wt cut off spin columns (Sartorius cat. No. VSII5RHO2). 7) These were spun at 3,000rpm for 30 minutes. 8) The system was topped up to 15m1 with 50mM TRIS buffer and respun. 9) StepS was repeated twice more. 10) The samples were pooled and topped up to the original volume. !0) The blocker is flow ready to employ or storedat 4C prior to use.
Example 2
Aldicarb-PEG Blocker.
Aldicarb acetate ethyl ester was synthesised and then hydrolysed to give a yeoow oil which was a carboxylic acid substituted analoge of aldicarb (see Siew et. aL, International Journal Environ. Anal.
Chem 83, 417-426). The aldicarb-COOH (2.9 mg) was dissolved in dioxin (600ul). To this solution was added NHS (2.9 mg) in dioxin (150 urn). To the resulting mixture was added N'N'-dicyclohexyl-carbodiimide (5.8 mg) in dimethylfomamide (580 ul) and the mixture left shaking for 2 hours. At the end of this time a solution of diamino-PEG (as Ex. 1) (12.4 mg) dissolved in 0.1mM sodium bicarbonate solution (1.24 ml). The miture was left the stir overnight. This was diluted with tris/triton buffer and dialysed as set out in ex. 1. -
Example 3.
Dip-stick.
Two lines are deposited on a 30cm length of nitrocellulose using an IsoFlow unit. The nitrocellulose was UniStart CN 140 from Sartorius.A test line pfpolyclonal goat anti mouse JgG which binds to Fc regions on antibodies non-specifically (Sigma cat. No. M4280) diluted to 50% in phosphate buffered saline was employed. A control line of monoclonal anti-biotin (Bio-Desige eat no H20098M) was also deposited. The control line was deposited 13mm from the leading edge of the nitrocellulose and.
the test line was deposited 17mm from the leading edge of the nitrocellulose.
The IsoFlow deposition parameters were as follows.
Setup mOve menu Setup pump menu Parameter Setting Parameter Setting Dispense Distance 300mm Dispense Rate 0.1 OOul/rnm Dispense speed 50mm/s Aspirate Rate 8u1/s Return Speed 300mm/s Start pause -0.lOs Start position. 0mm Stop pause -0/lOs Return pause 1.OOs Syringe size lOOul Lower nozzles 0.50s Inlet volume 40u1 Raise nozzles 1.OOs Outlet volume 60u1 Following deposition each length of material was examined for faults and if present were marked and discarded post assembly.
Once examined and while the deposited lines were still visible the bands were dried using a hair drier set to maximum. Following drying the material was stored in a thy environment.
The specific anti BE line was layed down. Monoclomal antibody specific to BE (East Coast Biologicals cat. No. P01-99-1 1M-P), pre-diluted to 300-3SOugIml in purified eater, was conjugated to BioAssay Works gold ( BAW gold conjugation kit). Once conjugated the gold can be stored at 2-8C prior to spraying on a glass fibre (or nitrocellulose) membrane.
To form a control biotin was conjugated to bovine serum albumin and coated onto) OD 1.0 colloidal gold supplied by British Biocell International. Incubation of a 1mg/nil solution of the conjugated biotin-ESA to the gold was effected whist mixing for 30 minutes at ambient temperature. Following incubation the colloidal gold was centrifuged at 13,000 rpm for 6 minutes, supernatent was discarded and the pellet resuspended in Ms buffered saline pH 8.2 containing triton X-100 and 1% BSA at a concentration equivalent to OD 0.5.
Once prepared the colloidal gold conjugates were mixed in the ratio I part control line gold to one part specific BE marker gold and I part of sucrose solution in tris buffered saline pH 8.2.
The membrane (conjugate release pad) was 27mm wide and supplied on a reel (Whatman, Standard 14 Part Number 8133- 2750). It was cut into 30cm lengths for spraying.
The gold was air brushed onto the membrane using the IsoFlow using the parameters given above except the setup move menu dispense speed was 30mm/s and the setup pump dispense rate was 0.8u1/mm.. The gold was sprayed at a height of 5mm above the conjugate pad at 4psi and 10mm from the leading edge of the -.
Once deposited the band of material were dried for three hours at 37C in an incubator before being stored in a thy environment.
The binding material was di-BE-polethyleglycol (conjugated through amino groups) as described in example 1. This material had been scanned from 200-SOOmu on a spectrophotometer to confirm freedom from unconjugated BE.
The binding material was diluted 1:1 with Ms buffered saline pH 8.2 containing triton X-100 and 1% BSA. The mixture was sprayed onto the conjugate pad 20mm from the leading edge using the IsoFlow using the parameters set out above except that the setup pump dispense rate was 0.4ugfmm. Following deposition, the material was dried for 3 hours at 37C in an incubator before being stored in a dry environment.
Once the components were prepared they ware assembled into a working test. All components were mounted onto self adhesive cards (G+L Precision). Cards were 0.Olinch white vinyl with GL- 187 adhesive, 75mm by 3000mm.
The nitrocellulose membrane was applied to the adhesive first, with leading edge 25mm from the base of the card. To the top of the card a strip of absorbent paper was added to form a sink (Whatman, CF6 Part Number 8116-2750). This was supplied as a reel of material 27mm wide so there was a 2mm overlap with the nitrocellulose. The conjugate pad was then applied to the base of the pad with a 2mm overlap with the nitrocellulose.
The assembled cards were then cut into 5mm strips ready for use.
When tested the dip sticks were able to detect BE in samples of spiked urine at concentrations of l0ngfml (Lowest éoncentration in test) lOOng/ml, 300ng/mI, 1,000ng'ml and l0,000ngfml demonstrating increasing intensity of the detection line was concentration increased.
Example 4.
Preparation of Various Blockers Or Use in Assay for Use in Methamplietamine Assay.
Chemistry To aw-di-succinimidyl ester poly(ethylene glycol) Mol wt 20,000 (9.9mg,4.95x1(r'mmol) in dioxan (ImI) followed by di-isopropylethylamine (0.02m1) was added N-(4-aminobut methyl R1s)-1-methy4..
phenylethylamine (5.0mg1 0.0227mmo1) in dry dlbxan (0.2m1). The reaction mixture was shaken for23..hours at 20-25°C. The mixture was diluted then dialyzed against 50mM of Tris btjfferat.pH 7.4 (4x 5L) using at 10,000 molecular weight cut oft membrane. The resulting solution GRD-55 (6.204g) was slightly hazy in appearance.
To BSA (26.4mg) in water (4m1) was added NEtS (2I.3rng,Oi8mrnoj) in water (0.5m() followed by EDC (40mg, O.I93mmol) in water (0.5m1). The mixture was shaken for 15 minutes at 20-25°C.
( I.8mg1 0.0081 mmol) in dioxan (0.2m1) was added followed by dIISOPropylethyIamifl(*321) The mixture was shaken f or 18 hours at 20250c To KU-I (20mg) in water (4m1) was added NHS (24mg,0.2lmmol) in water (0.5m1) followed by EDC (39mg, 0.l89mrnol) in water (0.5m1). The mixture was shaken for 15 minutes at 20-25°C;-tJ-(êaminobutyl)-N-methyl-N{(1S)-1-methyl-2-phenylethyl]arnine (1.8mg, 0.0081 mmcl) in dioxan (0.2ml) was added followed by di-isopropylethylamine (0.02m1). The mixture was shaken for 18 hours at 20-25°C.
The above materials were dialysed against 50mM ills buffer at pH 7.4 containing sodium azide using a 10,000 molecular weiOht cut off membrane.
BCA protein assay gave concentrations of 2.2mg/mi and 1.9 mg/mI respectively.
Chemistry To N-(4-aminobutyl)-N-methyl-N-[(1 S)-1-methyl-2-phenylethyl]amine ( 10.4mg, 0.0472 mmcl) in dioxan (0.5m1) was added 0.41 ml of a succinic anhydride (6.1 mg in 0.5m1 dioxin). The reaction mixture was heated at 70°C for 18 hours.
CouDlinQ to. PEG DLC method To 0.455m1 of the above solution was added NHS( 14.8mg,0.l28mmol) in dioxin (0.lrnflfollowed by DIC (18.5p1,0.ll9mmol). The mixture was shaken for 20 minutes then added 0 Otbis (2-aminoethyl)-polyethyleneglycoi 20,000 (8.0 mg, 3xlo4mmot) in dioxan(05ml). The réactión las shaken for 18 hours at 20-25°C. The solution was dialysed against 4x5L of 10% ethanol! water using a 10,000 molecular weight cut off membrane to yield 5.678g of conjugate solution.
BOP method To O,O-bis (2-aminoethyl)-polyethyleneglycol 20,000 (5.9 mg, 2,9xlcT'mmol) in dioxan (0.4 ml) was added di-isopropylethylamine (0.045m1, 0.236mmo1) and BOP (53mg, 0.1 l9mmol) dissolved in dioxan (0.4m1) ,DMF (0.6m1).
0.455ml of the succinate solution was addedand the mixture shaken for 18 hours at 20-25°C. Dialysis was-asabovSind yielded 11.205g of solution.
Example 5.
Preparation of Blocker for Use in Amphetamine Assay.
To aiw-di-succinimidyl ester POlY(ethylene glycol) Mol wt 20,000 (I7.6mg,8.8x1o-4o) in dioxan (O.4ml), NI-IS (i4.7mg, O.l27mmol) in dioxan (0.2m1) was added followed by D1C (l8.Spl, 15mg, 0.1 I9mmol) The reaction mixture was shaken for 48 hours.
diamine (2Img1oiolmmol) in dioxar, (0.2 ml) was added followed by di-IsOpropylethyiajr, (O.036m1) The reaction mixture was shaken for 24 hours at 20-25°c. The mixture was then dialyzed against deionised water containing 10% methanol (4x 51) using a 10,000 molecular weight cut off membrane The resulting Solution GRDL89 (lG.O82g) was slightly hazy.
Amphetamine B% To BSA (24.8mg) in water (4m1) was added NHS (22.2mg0.l93mmol) in water * (0.5m1) followed by EDC (41mg, 0.l99mmol) in water (O.5m9. The mixture was shaken for 15 minutes at 20-25°C. N-f(1S)-1-methyl-2-phenylethyljbutane-14-diamine ( 2.7mg, 0.013 mmd) in dioxan (0.2ml) followed by di-isopropylethylamine (0.02m1). The mixture was shaken for 18 hours at 20-25°C. The above material was dialysed against 50mM Iris buffer at pH 1.4 containing sodium addeUéiñOa 10,000 molecular weight cut off membrane. BCA protein assay after dialysis gave a concentration of 1.GmgImI. _____________
Example 6.
Preparation of Blocker for Use in Aldicarb Assay.
ChemIsti U GH,
HIXYNH
C
Np1,4'E04M2 / NOHOOs To aldicarb carboxylic acid (11.0mg, 0.O4lmmoI) in dry dioxan (2.2rnt) was added NHS (11.5mg,0.lOmmoI) in dry dioxan (0.7m1) followed by DCC (29.Omg,O.l4mmOl) in dry dioxan (2.lml). The reaction mixture was shaken foat25°C. _____-PEG wuui olecular weight To 6K PEG-diamine (5.0mg, 8.3x1 O4mmol) in DIM NaHCO3 (1.5m1) was added activated aldicarb carboxylic acid solution prepared as above, (1.67m1,0.Ol56mmol) The mixture was then shaken for 18 hours.
PEG 10.000 Molecular weight To 10K PEG-diamine (8.1mg, 8.lxlO4mmol) in 0.IM NaHCO3 (1.5m1) was added activated aldicarb carboxylic acid solution (1.67mI,00156mmol) The mixture was shaken for 18 hours.
PEG 20.000 Moleculér weight To 20K PEG-diarnine (14.9mg, 7.45xlcr'mmol) in 0.IM NaHCO3 (1.5m1) was added activated aldicarbcarboxylicacid sqjtion (t67m1, 0.Ol5Ommol). The mixture was shaken for 18 hours.
The above materials were dialysed separately against5OmM Tris buffer (5x5L) at pH 7.4 containing sodium azide using a 2,000 molecular weight cut off membrane. -Dialysis yielded 924Sg of solution for the BK PEG( GRD-54-1), 8.955g for the 10K PEG (GRD-54-2) and 8.800g for 20K PEG(GRD-54-3).
Lateral Flow Data With the 20,000 dalton PEG-Aldicarb assigned 100% blocking efficiency, 10,000 and 6.000 PEG-Aldicarb were 90% and 80% respectively.
Example 7.
Preparation of Various Blockers From DiamMo Terminated Polyehthylene Orlycols.
Dim PEG-B1ocke, All blockers were originally prepared as follows using a 10 IbId excess of antigen to PEG-NRj groups. The PEG-antigen complexes were originally dialysed in Trig-Triton buffer as given below as that was the buffer used in our EUSA and Dipstick assays.
The Triton has a large absorbanc at 280nm which makes it very difficujt to analyse the resulting conjugates. We now therefore routinely dialyse the conjugates in 10-25mM Sodium Phosphate buffer p1-17.5 (or even in water). This makes analysis of the final conjugates much easier Bdnzoyleegonlne to PEGQ1J Benzoylecgonine(13E) is the metabolite of cocaine, antibodies to BE cross react 100% with Cot
N
BE
4mg benzoylecgonjn (BE) is dissolved in 500u1 thy dioxan and this has 4mg N- Hydmxysicinj,e (NHS)added to it in another SOOuI dioxan. 8mg of I -EthyI-3-[3-dimethylan1JnopmpyqA:j hydrochloride (EDC) is then suspended in Imi dioxan (does not completely dissolve) and immediately added to the BE/Mis mix. Stable BE-MiS esters are produced as the mixture is left shaking at ambient temp for 2 hours.
After 2 hours 11mg of PEG I}ldissolvj in Imi of 0. hit Sodium Bicarbonate is added. The BE-NTIS residues couple via amide bonds to the PEG-NH2 groups with the regenerstion of flee NTIS. This is left with shaking 0/n for PEG-(NH-CO..B complexesto form.. Ther nmixbthJi.,!imi withTijsftrfton bufferand dialysed for 2-3 days against 51 Tris(l'riton buffer with 2-3 changes of buffers day Notes. Has to be EDC which is a water soluble carbodilmide, other carbofjiimjdes do not worlç possibly due to BE crystals containing water. Amount of BE added is approx a 10 fold excess to amount required to bind to both ends of the PEG.
BE MW is 365 x 2= l3Omg BE = 20,000mg PEG 36.Sug of BE is required to bind to both ends of 1mg PEG.
4mgBE= hlmg PEG at lOx excess PEG-(NH was added hi Bicarbonate (pH approx 8.4)to maximise formation of amide bonds between BFJ-NHS ester group and PEG amine group. TrWTritoij buffer is 50mM Tris-HCI buffer pH L4 containing 0.05% Triton LI 00.
Aldicarb to PEG(N112h Aldicarb acetate ethyl ester was synthesised and this was then hydrolysed to give a yellow oil which was a carboxylic acid substituted analogue of aldIcarb (as previously described, Siew et at, Intern I Environ. Anal. (Them. 83,417426). CH3
CH3 0 Aldicarb-COOH 2.9mg Aldicarb-COOH was dissolved in dioxan (600u1) and 2.9mg NTiS was added in another 150u1 dioxan. 5.8mg N,NtOicyclohexylCarbodiimide (DCC) dissolved in SSOul Dimethylfbrmamide(DMJt) was added and the mixture left shaking lbr 2hour to form Aldicarb-NHS esters. Alter the 2 hours 12.4mg PEG-(NH dissolved in 1.24 ml of 0. 1M Sodium Bicarbonate was added the mixture was left to shake o/n.
This was then diluted to l2.4m1 with Tris'Triton buffer and dialyse for 2-3 days against 51 Tristfliton buffer with 2-3 changes of buffer a day Note;-Again a lOfoId excess of Aldicarb to PEG-(NH2h Aldicarb acid MW 234 PEG-(NH MW2O,000 Therefore 468mg Aldicarb = 20000mg PEG (2 reactive amines) 23.4ug lmg PEG 234ug= lingat lOx excess 2.9mg = 12.4mg PEG Paraquat-PEC(N112)2 To 6mg Paraquat-hexanoic acid derivative (see Anal Chem 58,1866-1873) in 400u1 water was added 6mg NTiS in 600ul pure water. 30mg EDC was then added to the paraquat/NHS mix. This was left for only 15 miii as Paraquat-NHS is unstable in water (NTIS esters are stable in organic solution but paraquat is not soluble in orgaics) and 16mg PEG-(NH2)2 was added in 1.6m1 0. lM Sodium Bicarbonate. This was left 0/n, then made up to 16m1 with Tris/Triton buffer and dialysed as abovt Paraquat hexanote acid Chiorpyrifos-PEG(Nflth o HO Chiorpyrifos carboxylic acid 5mg Chlorpyrifos-carboxylic acid derivative (Flapten 2, Bull. Korean. Chem. Soc 2002, 23,481-487.)was dissolved in lad DMF followed by the addition of 5mg MIS in O.iml DMF and 5mg DCC in 05m1 DMF. This was shaken for 2hr for Chlorpyrifos-NHScsters to form. 11.5mg PEG-(N112h was then added in 1.155 50mM Sodium Phosphate pH 7.5. (Chlorpyrifos hydrolyses rapidly at pit>t0 so you do not couple it to PEG- (NH in bicarbonate As done with the other hapteus) Leave a/n with shaking, make up toll 3m! final volume with Tris/Triton and again dialyse as above Note;-We now dissolve the ?EG-(NH2h in 25s of dioxanfinstead of buffer). The chlorpyrifos-NHS will stably couple to the PEG amine groups in this organic solution.
Dialysis is then carried out in Phosphate buffer at pH7.O. This maximises the stability of the PEG-Chiorpyrifos conjugates cA$VtOL& I PRorocots A-CTJ MS&-dVtgLy M&r(+OAS aurnmary rrowcoi For BioAssay Works 4Onm Colloidal Gold Assessment Antibody concentration used can be between O.3-l.SmglniI it can also be either Whole or Fab fragments. You should also be able to use ScFv coated on gold as well Method: o Dilute the 4Onm Colloidal gold one in three (E OD 5.0) in ultrapure water.
o Place OimL of the gold sot into ten labelled test tubes and add 0.2mL of ultrapure water to each tube.
o Prepare in separate labelled tubes the following mixtures of buffeiz in -Tube Number pH _________ __________ 1 5.4 18 2 2 ____ 16 4 3. 7.3 12 8 4 7.8 8 12 4 16 Tube Number pH Buffer C -Buffer D 6. 8.4 10 0 7 8.8 16 4 8 9.2 12 8 9 9.6 8 12 ioi. 4 --16 o Transfer 3p1 of each buffer to the correspondingly numbered colloidal gold containing tube.
o Gently vortex mbc o Md l5pL of the antibody (250-35OpgImL) to each tube.
o Gently vortex mbc.
o Incubate static for 30 mins.
o Add 3OuL of the supplied blocking solution to each tube.
o Gently vortex mk o Gold Is ready for testing.
Membrane Depolition Test line deposition for whole antibody uses a mouse IgO (Fc specific) Test line for Fab fragments uses a mouse IgG (tab specific) Deposition of MAb a-biotin as Control line.
ikatedais: MM a-bjc,fip Blo Design Goat a mouse IgG (Pc specific) Sigma 1mg/mi Goat anti mouse IgG (Fab specific) Sartorius Membrane Unisart CN 140 10mM PBS Method: Standard machine programme: Une Deposition Setup Move Menu Parameter Setting Dispense Distance 300mm Dispense Speed 50mm/s Return Speed 300mm/s Start position 0mm Return Pause tOOs Lower Nozzles OSOs Raise Nozzles taOs Setup Pump Menu(s) Parameter Setting Dispense Rate O.lOOplJmm Aspirate Rate OpL/s Start Pause alas Stop Pause -0.lOs Sytinge Size lOOiL Inlet Volume 4OijL Outlet Volume 6OpL MAtP a-biotin diluted 1mg/mi in PBS and the Goat a mouse igG (Fc specific) diluted 1mg/mi in PBS.
30cm bands of nilmoellulose cut from the reel and a fine drawn on the reveSe (mylar backed side 3mm from either edge -designated the top). Bands transferred and lines drawn one band at a top ensuring orientation (black line on the top furthest away from operator). Sbc 30cm bands were deposited in total.
After three bands deposited these are dried using the hair drier.
Test line Can vary from 5mm from the base of the strip to 13mm and the control linefrom 10mm tol8mmfromthebaseofthestrip.
Membrane stored as bands in air tight container with silica gel.
conlucate ned sPravl!!g t Deposition gold, buffer and blocker.
Materials: Conjugated gold -Analyte conjugated to gold Control gold-Biotin BSA conjugated to gold.
Assay Buffer -Trizma Base 50mM plus NaCL 154mM pH 8.2 With-1% (w/v) Bovine Serum PJburnin (BSA) O.l%(v/v)Trftonx100 0.1% (wlv) NaN3 Assay Block-Analyte conjugated to Bis PEG 20,000 concentration adjusted to concentration to give maximum of 4 passes.
50% sucrose solution.
ACS water.
Spray positions and spray order 1' Gold conjugate position-Gold sprayed in middle of conjugate pad 2 passes.
2x1 Buffer position Buffer sprayed 5mm from bottom of conjugate pad 2 passes 3td Blocker position-Blocker sprayed 5mm from top of conjugate pad 4 passes two on each side on top of each other. Dy using hair dryer between each past Method 30cm bands of conjugate pad are cut from the reel. The right hand bottom corner Is cut to Identify the bottom edge of the pad.
Sloth gold and analyte gold conjugates are mixed 1:2 to this is added I part ACS water and I part 50% sucrose.
This is now ready for spraying using the standard machine settings see below.
Dry using low setting on hair dryer between each line deposited and Shrs at 37°C Between spraying of buffer and blocker.
Standard machine programmes: Move menu Parameter Setting ______ ______ _____________ Gold Block Buffer __________ Dispense Distance 300mm 300mm 300mm ___________ Dispense Speed 30mm/s 30mm/s 30mm/s - ___________ Return Speed 300mmIs 300mm/s 300mm/s __________ Start position 0n 0mm 0mm ____________ Return Pause Laos 1.OOs -1.OOs ___________ Lower Nozzles 0.50s 0.50s O.SOs ___________ Raise Nozzles i.oos 1.OOs 1.OOs PMrnP menu rameter Setting _________ _________ -Gold Block -Buffer __________ Dispense Rate pppmm 0.8pIJmm 0.8pL/mm __________ A!Pzrate Rate 4pUs pL/s ________ __________ Start Pause aios -O.lOs -0.iOs ___________ Stop Pause -O.lOs -tiOs -0.iOs SylingeSize 25QpL 25OpL 250pL _____________ Inlet Volume ________ 40p1 40pL ____________ Outlet Volume -SOpL 80p1 6OpL 30cm bands of conjugate pad are cut from the reel. The right hand bottom corner is cut to identify the bottom edge of the pad.
further Commentary Commercial antibodies may be employed when available. If no antibodies easily obtained commercially they may be raised by standard methods such as the following.
The antibody against chlorpyrifos was raised by the following schedule: day 0, primary immunisation 100 pg in Complete Freund's; day 16, first boot 100 pg in Incomplete Freund's; day 28 second boost 100 pg Incomplete Freund's; day 63 third boost in Incomplete Freund's; day 112 fourth boost for fusion; day 116 fusion. The immunogen was chlorpyrifos-KLH conjugate mice spleens were fused with myeloma line NS-1.
The antibodies against aldecarb were made on the same protocol using aldecarb-BSA conjugate.
Antibodies against methamphetamine were made using a mixture of amphetamine BSA and methamphetamine BSA. Four immunisations of pg, the first in Freund's Complete and the other three in Freund's Incomplete were used. Spleens were fused to [151 myeloma and screened against amphetamine and methamphetamine. The antibodies were very sensitive to methamphetamine and about 1000 fold less sensitive for amphetamine.
Commercial antibody against amphetamine was used.
The antibody against paraquat was raised by immunising with paraquat-KLH on the following schedule: day 0, primary immunisation 100 pg in TitreMax Gold; day 15 first boost 100 pg in TitreMax Gold; day 28 second boost 100 pg in TitreMax Gold; day 37 fourth boost for fusion; day 41 fusion. Mouse spleens were fused with myeloma line NS-1. Clones were screened using competitive Eliza and positives selected, single cell cloned and screened to stable clone.
The Immunogen used reflect the binding material so that the antibodies produced will potentially bind both to the hapten and the binding material.
It is desired for a competition to be able to take place between these agents in the liquid phase as it travels throughout the device.
Hence, in order to produce the immunogen for raising antibodies to methamphetamine, methamphetamine is linked to a -(CH2)4NH group by reaction with 4-bromobutylphthalamide followed by hydrolysis. This amine is then coupled to BSA using a water soluble carbodiimide such as N-(3dirnethylaminopropyl)-ethyl-N-carbodiimide (EDC) Similarly the paraquat antibody is raised using a paraquat conjugate via a -(CH2)5NH2 linker (which is commercially avallable). Aldecarb conjugate can be derived by activation of the aldecarb acid with NHS (N-.
hydroxysuccinamide) and reacting this with the protein, for example at pH9. With chlorpyrifos (also called herein chiorpyriphos), the analogue with the six carbon linker is obtainable by reaction with aminocaproic acid, activated with NHS and coupled to the protein.
The skilled worker is familiar with the chemistry required once the principles of the assay are read herein. The concept of close structure analogue is similarly well understood by the skilled worker as very many diagnostic systems rely on this concept generally in order to work. The analogue will contain sufficient structural features in common with the hapten to be able to compete with it for sites on the antibody; thus the relevant epitope will be preserved. Such analogues are often esters of acid groups or esters or amides of hydroxyl or amino groups in the hapten or compounds wherein a hydroxyl group or amino group are substituted by alkyl or substituted alkyl groups or the like. The skilled worker will be fully familiar with the concept.
Paragraphs of the invention 1. An assay device which comprises a permeable material such that when as aqueous liquid is contacted with a first part of the permeable material it permeates to a second part of the permeable material, said permeable material having a first zone and a second zone disposed so that when the aqueous liquid is contacted with the first part of the permeable material it passes first through the first zone and then into the second zone as it permeates to the second part of the permeable material; said first zone containing a signal generating means labelled with an antibody against a hapten; said first zone also containing a binding material for said antibody against the hapten; said second zone contains a locating means for said antibody against the hapen such that it binds to the antibody present on the signal generating means labelled with an antibody which has bound hapten but does not bind to antibody present on the signal generating means which has bound the binding material for said antibody against the hapten; the signal generating means being such that a signal is generated on binding to said locating means; wherein: (a) the locating means is not a specific binder for the antibody against the hapten and/or (b) the locating means is an antibody against the Fc region of the antibody against the hapten and/or (c) the binding material for the antibody against the hapten is free of hapten and/or hapten analogue and/or (d) the binding material is hapten or close structural analogue covalently bound to a synthetic hydrophilic molecule of molecular weight grater than 2000 and/or (e) the binding material has two hapten or close structural analogues.
2. A device as described in paragraph I in the form of a dip stick.
3. A dip stick as described in paragraph 2 wherein the locating means is an antibody against the Fsubc region of the antibody against the hapten.
4. A dip stick as described in paragraph 3 wherein the locating means is a polyclonal antibody.
5. A dipstick as described in any of paragraphs 2 to 4 wherein the signal generating means is coloured gold microparticles.
6. A dipstick as described in any of paragraphs 2 to 5 wherein the binding material is a large molecule, for example of molecular weight 5000 daltons or more, to which hapten or close structural analogue thereof is bound.
7. A dipstick as described in paragraph 6 wherein the large molecule is a hydrophilic synthetic molecule.
8. A dipstick as described in paragraph 7 wherein the polymer is polyethylene glycol.
9. A dipstick as described in paragraph 8 wherein the polyethyleneglycol has a molecular weight of 5000 to 60000 daltons, more aptly 10000 to 40000 daltons, and preferably from 20000 to 30000 daltons.
10. A dipstick as described in any of paragraphs 6 to 9 wherein the binding material has more than one molecule, preferably 2 molecules, of hapten or close structural analogue bound thereto.
11. A dipstick as described in any of paragraphs 2 to 10 wherein the hapten to be determined is a drug of abuse or environmental pollutant.
12. A dipstick as described in paragraph 11 wherein the drug of abuse is cocaine amphetamine or methamphetamine.
13. A dipstick as described in paragraph 11 wherein the environmental pollutant is aldicarb, paraquat or chlorpyraphos.
Claims (14)
- Claims 1. An assay device which comprises a permeable material such that when an aqueous liquid is contacted with a first part of the permeable material it permeates to a second part of the permeable material, said permeable material having a first zone and a second zone disposed so that when the aqueous liquid is contacted with the first part of the permeable material it passes first through the first zone and then into the second zone as it permeates to the second part of the permeable material; said first zone containing a signal generating means labelled with an antibody against a hapten; said first zone also containing a binding material for said antibody against the hapten; said second zone contains a locating means for said antibody against the Q hapten such that it binds to the antibody present on the signal generating means labelled with an antibody which has bound hapten but does not N... bind to antibody present on the signal generating means which has bound the binding material for said antibody against the hapten; Q 20 the signal generating means being such that a signal is generated on binding to said locating means; wherein the binding material is hapten or close structural analogue covalently bound to a synthetic hydrophilic molecule of molecular weight greater than 2000.
- 2. A device as claimed in claim 1 in the form of a dip stick.
- 3. A dip stick as claimed in claim 2 wherein the locating means is an antibody against the Fsubc region of the antibody against the hapten.
- 4. A dip stick as claimed in claim 3 wherein the locating means is a polyclonal antibody.
- 5. A dip stick as claimed in any of claims 2 to 4 wherein the signal generating means is coloured gold microparticles.
- 6. A dip stick as claimed in any of claims 2 to 5 wherein the synthetic hydrophilic molecule has a molecular weight 5000 daltons or more to which hapten or close structural analogue thereof is bound.
- 7. A dip stick as claimed in claim 6 wherein the hydrophilic synthetic molecule has a molecular weight of 5000 to 60000 daltons.
- 8. A dip stick as claimed in claim 7 wherein the polymer is polyethylene glycol.
- 9. A dip stick as claimed in claim 8 wherein the polyethyleneglycol has a molecular weight of 10000 to 40000 daltons, and preferably from 20000 to 30000 daltons.
- 10. A dip stick as claimed in any of claims 6 to 9 wherein the binding Q material has more than one molecule, preferably 2 molecules, of hapten or close structural analogue bound thereto.
- 11. A dip stick as claimed in any of claims 2 to 10 wherein the hapten Q 20 to be determined is a drug of abuse or environmental pollutant. (\J
- 12. A dip stick as claimed in claim 11 wherein the drug of abuse is cocaine amphetamine or methamphetamine.
- 13. A dip stick as claimed in claim 11 wherein the environmental pollutant is aldicarb, paraquat or chlorpyraphos.
- 14. A device as claimed in any of claims 1 to 13 wherein the hapten to be determined is a mycotoxin.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0707870.2A GB0707870D0 (en) | 2007-04-23 | 2007-04-23 | Assay Devices and Methods and Components for use Therein |
| GB0910053A GB2461615B (en) | 2007-04-23 | 2009-06-11 | Assay devices and methods and components for use therein |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| GB201010247D0 GB201010247D0 (en) | 2010-07-21 |
| GB2475579A true GB2475579A (en) | 2011-05-25 |
| GB2475579B GB2475579B (en) | 2011-12-21 |
Family
ID=43928050
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB1010247.3A Expired - Fee Related GB2475579B (en) | 2007-04-23 | 2009-06-11 | Assay devices and methods and components for use therein |
Country Status (1)
| Country | Link |
|---|---|
| GB (1) | GB2475579B (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0279097A2 (en) * | 1987-02-17 | 1988-08-24 | Genesis Labs, Inc. | Immunoassay test strip |
| US4959305A (en) * | 1986-06-18 | 1990-09-25 | Miles Inc. | Reversible immobilization of assay reagents in a multizone test device |
| US5451504A (en) * | 1991-07-29 | 1995-09-19 | Serex, Inc. | Method and device for detecting the presence of analyte in a sample |
| US5942407A (en) * | 1996-06-25 | 1999-08-24 | Immunomatrix, Inc. | Light-emitting immunoassay |
| WO2000000826A1 (en) * | 1998-06-30 | 2000-01-06 | Cambridge Sensors Limited | Immunometric assay |
-
2009
- 2009-06-11 GB GB1010247.3A patent/GB2475579B/en not_active Expired - Fee Related
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4959305A (en) * | 1986-06-18 | 1990-09-25 | Miles Inc. | Reversible immobilization of assay reagents in a multizone test device |
| EP0279097A2 (en) * | 1987-02-17 | 1988-08-24 | Genesis Labs, Inc. | Immunoassay test strip |
| US5451504A (en) * | 1991-07-29 | 1995-09-19 | Serex, Inc. | Method and device for detecting the presence of analyte in a sample |
| US5942407A (en) * | 1996-06-25 | 1999-08-24 | Immunomatrix, Inc. | Light-emitting immunoassay |
| WO2000000826A1 (en) * | 1998-06-30 | 2000-01-06 | Cambridge Sensors Limited | Immunometric assay |
Also Published As
| Publication number | Publication date |
|---|---|
| GB201010247D0 (en) | 2010-07-21 |
| GB2475579B (en) | 2011-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3358737B2 (en) | Assays with improved dose response curves | |
| AU726869B2 (en) | Indirect label assay device for detecting small molecules and method of use thereof | |
| EP1185870B1 (en) | Bidirectional lateral flow test strip and method | |
| US8313955B2 (en) | Devices and methods for detecting analytes | |
| US6699722B2 (en) | Positive detection lateral-flow apparatus and method for small and large analytes | |
| JP2807565B2 (en) | Threshold ligand-receptor assay | |
| US5763262A (en) | Immunodiagnostic device | |
| JPH0814579B2 (en) | Measuring method and reagent for specific binding substance | |
| JP2010512537A (en) | Indirect lateral flow sandwich assay | |
| EP0462376A2 (en) | Conjugate recovery binding assays | |
| CN101371140A (en) | Anti-drug antibody assay | |
| US4837145A (en) | Layered immunoassay using antibodies bound to transport particles to determine the presence of an antigen | |
| JPH06508214A (en) | Methods and reagents for performing ion capture digoxin assays | |
| CA2110049C (en) | Devices for performing ion-capture binding assays | |
| WO1994003811A1 (en) | Immunological detection using two detectable labels | |
| US8389296B2 (en) | Assay devices and methods and components for use therein | |
| JPS62502495A (en) | Direct homogeneity test | |
| Gerdes et al. | Development of a displacement immunoassay by exploiting cross-reactivity of a monoclonal antibody | |
| KR100215552B1 (en) | Detection strip od narcotics for on-site test | |
| GB2475579A (en) | Dipstick immunoassay with capture zone comprising immobilised hapten | |
| EP1086375A1 (en) | Colloidal colorimetric flow through and lateral flow assays utilizing soluble submicron particles | |
| JPH0731203B2 (en) | Method for quantitatively measuring polyvalent antigen, reagent therefor, and method for producing receptor | |
| CN113811770A (en) | Interference-suppressing pharmacokinetic immunoassay | |
| KR970010983B1 (en) | Morphine test and detecting pad and manufacturing method therefor | |
| EP0653065B1 (en) | Separation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PCNP | Patent ceased through non-payment of renewal fee |
Effective date: 20200422 |